FI972793L - Nebivololin käyttö antiaterogeenisenä aineena - Google Patents

Nebivololin käyttö antiaterogeenisenä aineena Download PDF

Info

Publication number
FI972793L
FI972793L FI972793A FI972793A FI972793L FI 972793 L FI972793 L FI 972793L FI 972793 A FI972793 A FI 972793A FI 972793 A FI972793 A FI 972793A FI 972793 L FI972793 L FI 972793L
Authority
FI
Finland
Prior art keywords
nebivolol
antiatherogenic
agent
antiatherogenic agent
Prior art date
Application number
FI972793A
Other languages
English (en)
Swedish (sv)
Other versions
FI972793A0 (fi
FI118884B (fi
Inventor
Chaffoy De Courcelles Didie De
Anne Simone Josephine Lesage
Josepha Eduarda Maria F Leysen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of FI972793L publication Critical patent/FI972793L/fi
Publication of FI972793A0 publication Critical patent/FI972793A0/fi
Application granted granted Critical
Publication of FI118884B publication Critical patent/FI118884B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
FI972793A 1994-12-28 1997-06-27 Nebivololin käyttö antiaterogeenisenä aineena FI118884B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP94203775 1994-12-28
EP94203775 1994-12-28
EP9505174 1995-12-21
PCT/EP1995/005174 WO1996019987A1 (en) 1994-12-28 1995-12-21 Use of nebivolol as an anti-atherogenic

Publications (3)

Publication Number Publication Date
FI972793L true FI972793L (fi) 1997-06-27
FI972793A0 FI972793A0 (fi) 1997-06-27
FI118884B FI118884B (fi) 2008-04-30

Family

ID=8217503

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972793A FI118884B (fi) 1994-12-28 1997-06-27 Nebivololin käyttö antiaterogeenisenä aineena

Country Status (20)

Country Link
US (2) US5874461A (fi)
EP (1) EP0801564B1 (fi)
JP (1) JPH10511655A (fi)
KR (1) KR100264348B1 (fi)
CN (1) CN1167418C (fi)
AT (1) ATE214924T1 (fi)
AU (1) AU700364B2 (fi)
CA (1) CA2207333C (fi)
CZ (1) CZ287513B6 (fi)
DE (1) DE69526120T2 (fi)
DK (1) DK0801564T3 (fi)
ES (1) ES2176354T3 (fi)
FI (1) FI118884B (fi)
HU (1) HU226208B1 (fi)
NO (1) NO315687B1 (fi)
NZ (1) NZ298074A (fi)
PT (1) PT801564E (fi)
SI (1) SI0801564T1 (fi)
SK (1) SK282144B6 (fi)
WO (1) WO1996019987A1 (fi)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2176354T3 (es) * 1994-12-28 2002-12-01 Janssen Pharmaceutica Nv Uso de nebivolol como agente anti-aterogenico.
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
JP2000207219A (ja) * 1999-01-18 2000-07-28 Fujitsu Ten Ltd 車載端末とセンタ―との間の通信システム、及び、通信システムに使用する車載端末
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
HUP0303915A3 (en) 2001-01-26 2012-12-28 Merck Sharp & Dohme Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
DE60212801T2 (de) 2001-01-26 2007-02-01 Schering Corp. Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
EP1406608B1 (en) 2001-05-02 2009-07-29 Nitromed, Inc. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
ATE345793T1 (de) 2001-09-21 2006-12-15 Schering Corp Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
EP1558922B1 (en) * 2002-10-30 2013-02-27 Ampere Life Sciences, Inc. Identifying therapeutic compounds based on their physical-chemical properties
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
WO2005032544A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Treatment of mitochondrial diseases
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
PL1737847T3 (pl) 2004-07-30 2008-11-28 Torrent Pharmaceuticals Ltd Nebiwolol i jego farmaceutycznie dopuszczalne sole, proces ich przygotowania i kompozycje farmaceutyczne nebiwololu
AU2006210952B2 (en) * 2005-01-31 2011-08-04 Mylan Laboratories, Inc. Pharmaceutical composition comprising hydroxylated nebivolol
EA035619B1 (ru) 2005-06-01 2020-07-16 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Композиции для использования в способе лечения митохондриальных нарушений
US9278085B2 (en) 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
PL3456707T3 (pl) 2007-11-06 2020-09-21 Ptc Therapeutics, Inc. Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych
US20090181975A1 (en) * 2008-01-15 2009-07-16 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
CA2717734A1 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
MX2011002318A (es) 2008-09-10 2011-05-10 Edison Pharmaceuticals Inc Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
WO2010045220A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
EP2379710A1 (en) * 2008-12-19 2011-10-26 Schering Corporation Feed supplement for mammalian cell culture and methods of use
PT2424495T (pt) 2009-04-28 2018-03-13 Bioelectron Tech Corp Tratamento de neuropatia ótica hereditária de leber e atrofia ótica dominante com quinonas de tocotrienol
WO2011150859A1 (en) * 2010-06-04 2011-12-08 Comprehensive Drug Enterprises Ltd Oral meclizine aqueous formulations with taste flavoring agent
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
DE102014107132A1 (de) 2014-05-20 2015-11-26 Corden Pharma International Gmbh Verfahren zur Herstellung von Epoxiden die in der Herstellung von Nebivolol und dessen Derivaten einsetzbar sind
TW201615223A (zh) * 2014-10-24 2016-05-01 朗齊生物醫學股份有限公司 驅蟲藥臨床新應用
KR102626895B1 (ko) 2014-12-16 2024-01-18 피티씨 테라퓨틱스, 인크. (r)-2-하이드록시-2-메틸-4-(2,4,5-트리메틸-3,6-디옥소사이클로헥사-1,4-디에닐)부탄아미드의 다형성 및 무정형 형태
CN113024369A (zh) 2015-12-17 2021-06-25 Ptc医疗公司 用于治疗氧化应急障碍的化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1337432C (en) * 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
ES2176354T3 (es) * 1994-12-28 2002-12-01 Janssen Pharmaceutica Nv Uso de nebivolol como agente anti-aterogenico.

Also Published As

Publication number Publication date
MX9704669A (es) 1997-09-30
CA2207333A1 (en) 1996-07-04
EP0801564A1 (en) 1997-10-22
NO315687B1 (no) 2003-10-13
DE69526120D1 (de) 2002-05-02
CN1171739A (zh) 1998-01-28
CN1167418C (zh) 2004-09-22
AU700364B2 (en) 1999-01-07
ES2176354T3 (es) 2002-12-01
ATE214924T1 (de) 2002-04-15
NO972980D0 (no) 1997-06-26
FI972793A0 (fi) 1997-06-27
CZ191997A3 (cs) 1999-01-13
KR100264348B1 (ko) 2000-08-16
DK0801564T3 (da) 2002-07-15
SK85697A3 (en) 2000-04-10
PT801564E (pt) 2002-09-30
CZ287513B6 (en) 2000-12-13
NO972980L (no) 1997-06-26
US5874461A (en) 1999-02-23
SI0801564T1 (en) 2002-08-31
WO1996019987A1 (en) 1996-07-04
HU226208B1 (en) 2008-06-30
DE69526120T2 (de) 2002-11-28
JPH10511655A (ja) 1998-11-10
US6075046A (en) 2000-06-13
HUT77927A (hu) 1998-11-30
CA2207333C (en) 2006-10-17
SK282144B6 (sk) 2001-11-06
EP0801564B1 (en) 2002-03-27
AU4347796A (en) 1996-07-19
FI118884B (fi) 2008-04-30
NZ298074A (en) 2001-01-26

Similar Documents

Publication Publication Date Title
FI972793L (fi) Nebivololin käyttö antiaterogeenisenä aineena
BR9507179A (pt) Derivados de 3-aril-4-hidróxi-delta3-dihidrotiofena
FI963278L (fi) Verihiutaleen tuotantoa edistävä aine
DE69513300D1 (de) Bestimmungsverfahren
BR9509868A (pt) Fralda
DE69529223D1 (de) Prüfverfahren
DE69430587D1 (de) Pyrimidin-acyclonukleosid-derivate
DE69427296D1 (de) Gewürzmittel
FI960367A7 (fi) Uusia dialkoksipyridinyylibentsimidatsolijohdannaisia
BR9507892A (pt) Novos derivados de diamino-metilideno
KR960023412U (ko) 로터리 압축기의 압축장치
DE69510792D1 (de) Naphtochinonderivate
FI20041236L (fi) Silmänpainetta alentava aine
BR9509295A (pt) Escareador
BR9509877A (pt) Novos derivados de pirimidinilóxi-e piridimidinilamino- etilfenil-dioxolano
ITMI950222A0 (it) Tessuto
FI943921L (fi) Vapaan trypsinogeeni-2:n määritys
BR9508669A (pt) Novos derivados de taizoloÚ3,2-a¾quinolina e naftirina
KR960020013U (ko) 굳은 살 제거구
KR960020187U (ko) 저주파 전침기
PT101483A (pt) Instrumento cirurgico - porta/passa - fios
KR960004995U (ko) 높이조절이 가능한 곽티슈의 케이스
UA644S (uk) Мікро-еом широкого призначення
SE9403002D0 (sv) Desinfektionsvätska
KR960005992U (ko) 모니터의 케이싱

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118884

Country of ref document: FI

MA Patent expired